Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer

Molecular Radiotherapy ◽

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort

Journal of Nuclear Medicine ◽

10.2967/jnumed.121.261982 ◽

2021 ◽

pp. jnumed.121.261982

Author(s):

Jeremie Calais ◽

Andrei Gafita ◽

Matthias Robert Eiber ◽

Wesley Robert Armstrong ◽

Jeannine Gartmann ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Molecular Radiotherapy ◽

Phase 2 Trial ◽

Castration Resistant ◽

Prospective Phase

Neuroendocrine secretory profiles are not associated with treatment response to Lu-177-PSMA-617 radioligand therapy in patients with advanced metastatic castration-resistant prostate cancer

10.1055/s-0040-1708342 ◽

2020 ◽

Author(s):

T Derlin ◽

R Werner ◽

C Henkenberens ◽

TL Ross ◽

FM Bengel

Keyword(s):

Prostate Cancer ◽

Treatment Response ◽

Radioligand Therapy ◽

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Prostate Specific Membrane Antigen ◽

Radioligand Therapy ◽

Castration Resistant ◽

Specific Membrane

New combination therapies for castration-resistant prostate cancer

Oncology Abstracts ◽

10.1530/oncolabs.1.p031 ◽

2019 ◽

Author(s):

Mitchell G Lawrence ◽

Laura H Porter ◽

Daisuke Obinata ◽

Shahneen Sandhu ◽

Luke A Selth ◽

...

Keyword(s):

Prostate Cancer ◽

New Combination ◽

Combination Therapies ◽

The role of microbiota in driving castration-resistant prostate cancer

10.26226/morressier.5f69edb69b74b699bf38c5cf ◽

2020 ◽

Author(s):

Arianna Calcinotto

Keyword(s):

Prostate Cancer ◽

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

10.31525/cmr-1904aca ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

10.31525/ct1-nct03851640 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Efficacy And Safety ◽

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

10.31525/ct1-nct03874884 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

10.31525/ct1-nct03972657 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

10.31525/ct1-nct04070209 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽